Check Out The Clinical Stage Company Aiming To Beat Chronic Back Pain!
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is currently working on an FDA Phase II clinical trial for their autologous stem-cell therapy, BRTX-100, to help patients who suffer from single-disc-related Chronic Lumbar Degenerative Disc Disease.
Hear from expert, Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, as he discusses his work on those trials with BioRestorative Therapies in this must-see interview!
BioRestorative Therapies was founded by scientists committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.
Hear from expert, Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, as he discusses his work on those trials with BioRestorative Therapies in this must-see interview!
BioRestorative Therapies was founded by scientists committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.